Over 2 years, bulevirtide monotherapy reduced the risk for decompensation and mortality, but not hepatocellular carcinoma, among patients with hepatitis D virus and compensated cirrhosis compared with untreated patients. “Bulevirtide, the first-in-class entry inhibitor, has been approved by EMA for treatment of compensated chronic hepatitis delta,” Elisabetta Degasperi, MD,
Researchers identified bile duct dysplasia or cancer in most explanted livers with an indication of biliary dysplasia, although as many as 41% had no signs of neoplasia, according to a study of patients with primary sclerosing cholangitis. “Primary sclerosing cholangitis, in short PSC, is one of the leading causes of liver transplantation in the Nordic countries with a high risk of
Mebeverine not superior to placebo in pediatric IBS; active drug labeling improved efficacy healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
WASHINGTON — Once-daily etrasimod 1 mg and 2 mg was well-tolerated and sustained improvements in histological and endoscopic features of eosinophilic esophagitis, as well as patient symptoms, through 52 weeks of treatment, according to data.
“Etrasimod is a an oral, once-daily selective sphingosine 1-phosphate receptor modulator for the treatment of moderately to severely active
WASHINGTON — A blood-based screening test detected colorectal cancer with a sensitivity of 79.2% and a specificity of 91.5% among average-risk adults aged 45 to 85 years, according to research presented at Digestive Disease Week.
“Adherence to colon cancer screening tests is suboptimal with current options of stool-based tests and colonoscopy,” Aasma Shaukat, MD, MPH, director